Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Podcasts|November 13, 2009

Regulatory and Safety: Obesity Drugs

Diabetes & Obesity Series


Safety and Regulatory Aspects of Obesity Drugs

Subscribe to RSS feed of this series



Dr. David Orloff
Executive Director of Regulatory Affairs
Medpace



Dr. Orloff discusses the current and potential future regulatory issues for obesity and diabetes drugs, how FDA and industry is moving toward levels of safety for these drug classes.

Others in the Series




Related to this article